• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估疫苗上市后安全性面临的挑战:来自疾病预防控制中心的观察。

Challenges in evaluating post-licensure vaccine safety: observations from the Centers for Disease Control and Prevention.

机构信息

Immunization Safety Office, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

出版信息

Expert Rev Vaccines. 2019 Oct;18(10):1091-1101. doi: 10.1080/14760584.2019.1676154. Epub 2019 Oct 19.

DOI:10.1080/14760584.2019.1676154
PMID:31580725
Abstract

: Vaccination is one of the most successful and cost-effective public health interventions. Although vaccines undergo extensive safety and efficacy evaluations prior to licensure, vaccine safety assessment post-licensure is essential for detecting rare and longer-term adverse events (AEs) and maintaining public confidence in vaccines and recommended immunization programs. Despite the proven effect of vaccines to save lives and prevent disease and overwhelming evidence of vaccines' safety and societal benefit, like any drug, no vaccine can be considered as completely safe and completely effective. New vaccines continue to be introduced and require rapid safety assessment post-licensure through pharmacovigilance reports as well as epidemiologic studies to investigate any potential safety signals.: We discuss selected challenges for conducting pharmacovigilance and epidemiologic studies of AEs after vaccination in the United States using the post-licensure safety surveillance infrastructure of the Centers for Disease Control and Prevention (CDC).: The availability of specific post-licensure surveillance systems to monitor and study AEs after vaccination, such as the Vaccine Adverse Event Reporting System, the Vaccine Safety Datalink, and the Clinical Immunization Safety Assessment Project, each with its unique set of strengths and limitations, provide a harmonized and supportive approach to meet several of these barriers.

摘要

疫苗接种是最成功和最具成本效益的公共卫生干预措施之一。尽管疫苗在获得许可前要经过广泛的安全性和有效性评估,但在获得许可后对疫苗安全性进行评估对于发现罕见和长期的不良事件(AE)以及维护公众对疫苗和推荐免疫计划的信心至关重要。尽管疫苗在拯救生命和预防疾病方面的效果已得到证实,并且疫苗的安全性和社会效益的证据压倒性,但与任何药物一样,没有一种疫苗可以被认为是完全安全和完全有效的。新疫苗不断推出,需要通过药物警戒报告以及流行病学研究,在获得许可后快速进行安全性评估,以调查任何潜在的安全信号。

我们讨论了在美国使用疾病预防控制中心(CDC)的上市后安全性监测基础设施进行疫苗接种后不良事件(AE)的药物警戒和流行病学研究的一些选定挑战。

有专门的上市后监测系统可用于监测和研究疫苗接种后的 AE,例如疫苗不良事件报告系统、疫苗安全数据链接和临床免疫安全评估项目,每个系统都有其独特的优势和局限性,为应对其中的一些障碍提供了一种协调和支持的方法。

相似文献

1
Challenges in evaluating post-licensure vaccine safety: observations from the Centers for Disease Control and Prevention.评估疫苗上市后安全性面临的挑战:来自疾病预防控制中心的观察。
Expert Rev Vaccines. 2019 Oct;18(10):1091-1101. doi: 10.1080/14760584.2019.1676154. Epub 2019 Oct 19.
2
Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS).疫苗不良事件报告系统(VAERS)中的安全性监测。
Vaccine. 2015 Aug 26;33(36):4398-405. doi: 10.1016/j.vaccine.2015.07.035. Epub 2015 Jul 22.
3
Surveillance systems and methods for monitoring the post-marketing safety of influenza vaccines at the Centers for Disease Control and Prevention.美国疾病控制与预防中心监测流感疫苗上市后安全性的监测系统及方法
Expert Opin Drug Saf. 2016 Sep;15(9):1175-83. doi: 10.1080/14740338.2016.1194823. Epub 2016 Jun 16.
4
Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.免疫接种后安全性监测:疫苗不良事件报告系统(VAERS)——美国,1991 - 2001年
MMWR Surveill Summ. 2003 Jan 24;52(1):1-24.
5
Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015.美国 2006-2015 年带状疱疹减毒活疫苗(Zostavax®)上市后安全性监测:疫苗不良事件报告系统(VAERS)
Hum Vaccin Immunother. 2018;14(8):1963-1969. doi: 10.1080/21645515.2018.1456598. Epub 2018 May 18.
6
Post-licensure rapid immunization safety monitoring program (PRISM) data characterization.疫苗上市后快速免疫安全性监测项目(PRISM)数据特征描述。
Vaccine. 2013 Dec 30;31 Suppl 10:K98-112. doi: 10.1016/j.vaccine.2013.04.088.
7
The costs and effectiveness of large Phase III pre-licensure vaccine clinical trials.大型III期疫苗上市前临床试验的成本与效益
Expert Rev Vaccines. 2015;14(12):1543-8. doi: 10.1586/14760584.2015.1091733. Epub 2015 Sep 28.
8
Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience.人乳头瘤病毒 16/18-AS04 佐剂疫苗上市后安全性监测:超过 4 年的经验。
Pharmacoepidemiol Drug Saf. 2014 May;23(5):456-65. doi: 10.1002/pds.3593. Epub 2014 Feb 20.
9
Evaluation of 'SAEFVIC', A Pharmacovigilance Surveillance Scheme for the Spontaneous Reporting of Adverse Events Following Immunisation in Victoria, Australia.对“SAEFVIC”的评估,这是澳大利亚维多利亚州一项针对免疫接种后不良事件自发报告的药物警戒监测计划。
Drug Saf. 2017 Jun;40(6):483-495. doi: 10.1007/s40264-017-0520-7.
10
The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety.疫苗安全数据链接:监测疫苗安全的成功与挑战。
Vaccine. 2014 Sep 22;32(42):5390-8. doi: 10.1016/j.vaccine.2014.07.073. Epub 2014 Aug 6.

引用本文的文献

1
Pharmacoepidemiologic Research Based on Common Data Models: Systematic Review and Bibliometric Analysis.基于通用数据模型的药物流行病学研究:系统评价与文献计量分析
JMIR Med Inform. 2025 Jul 28;13:e72225. doi: 10.2196/72225.
2
Feasibility of cohort event monitoring and assessment of reactogenicity and adverse events among a cohort of AstraZeneca and Moderna COVID-19 vaccine recipients in Nigeria, 2021.2021年尼日利亚阿斯利康和莫德纳新冠疫苗接种人群队列事件监测及反应原性和不良事件评估的可行性
Vaccine. 2025 Apr 11;52:126907. doi: 10.1016/j.vaccine.2025.126907. Epub 2025 Mar 12.
3
Evaluation of Heterologous Effects of Travel Vaccines in Colorectal Cancer: A Database Study and a Cautionary Tale.
旅行疫苗对结直肠癌的异源效应评估:一项数据库研究及警示故事
Gastro Hep Adv. 2022 Apr 29;1(4):531-537. doi: 10.1016/j.gastha.2022.02.013. eCollection 2022.
4
Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe.美国 COVID-19 疫苗接种计划最初 6 个月期间接种 mRNA 疫苗的安全性:对疫苗不良事件报告系统和 v-safe 报告的观察性研究。
Lancet Infect Dis. 2022 Jun;22(6):802-812. doi: 10.1016/S1473-3099(22)00054-8. Epub 2022 Mar 7.
5
Tracking the progress in COVID-19 and vaccine safety research - a comprehensive bibliometric analysis of publications indexed in Scopus database.追踪 COVID-19 和疫苗安全研究进展——Scopus 数据库索引出版物的综合文献计量分析。
Hum Vaccin Immunother. 2021 Nov 2;17(11):3887-3897. doi: 10.1080/21645515.2021.1969851. Epub 2021 Oct 6.
6
From program suspension to the pandemic: A qualitative examination of Australia's vaccine pharmacovigilance system over 10 years.从项目暂停到疫情:对澳大利亚疫苗药物警戒系统 10 年来的定性研究
Vaccine. 2021 Sep 24;39(40):5968-5981. doi: 10.1016/j.vaccine.2021.07.059. Epub 2021 Aug 8.
7
Challenges in Phase 4 post-licensure safety studies using real world data in the United States: Hepatitis B vaccine example.在美国使用真实世界数据进行4期上市后安全性研究的挑战:以乙肝疫苗为例。
Vaccine X. 2021 Jun 11;8:100101. doi: 10.1016/j.jvacx.2021.100101. eCollection 2021 Aug.
8
Reactive arthritis after COVID-19 vaccination.接种 COVID-19 疫苗后的反应性关节炎。
Hum Vaccin Immunother. 2021 Sep 2;17(9):2954-2956. doi: 10.1080/21645515.2021.1920274. Epub 2021 May 25.
9
A guide to vaccinology: from basic principles to new developments.疫苗学指南:从基本原则到新进展。
Nat Rev Immunol. 2021 Feb;21(2):83-100. doi: 10.1038/s41577-020-00479-7. Epub 2020 Dec 22.